Put Options

14 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $2.72 Million - $3.55 Million
68,600 New
68,600 $3.55 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $11.6 Million - $12.9 Million
-200,000 Reduced 30.84%
448,500 $26 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $12.7 Million - $14.1 Million
200,000 Added 44.59%
648,500 $41.5 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $6.41 Million - $7.27 Million
-97,500 Reduced 17.86%
448,500 $31.1 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $23.9 Million - $28.3 Million
348,500 Added 176.46%
546,000 $39.3 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $22,997 - $13.6 Million
-176,900 Reduced 47.25%
197,500 $14 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $9.64 Million - $10.6 Million
132,800 Added 54.97%
374,400 $28.8 Million
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $10.9 Million - $13.1 Million
177,600 Added 277.5%
241,600 $17.6 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $9.66 Million - $10.5 Million
-156,000 Reduced 70.91%
64,000 $4.28 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $5.84 Million - $6.83 Million
106,500 Added 93.83%
220,000 $12.9 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $1.48 Million - $1.93 Million
30,000 Added 35.93%
113,500 $7.29 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $18.5 Million - $20.5 Million
-415,000 Reduced 83.25%
83,500 $3.79 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $13.7 Million - $16.4 Million
304,100 Added 156.43%
498,500 $23.8 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $11.7 Million - $12.7 Million
194,400
194,400 $11.9 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.